Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.97% 52.00 51.00 53.00 52.00 51.50 51.50 25,000 08:06:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 5.0 -3.1 -12.4 - 16

Cambridge Cognition Share Discussion Threads

Showing 426 to 449 of 450 messages
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
15/10/2020
12:38
S1234, Thank you very much, very helpful indeed.
w t tutte
15/10/2020
11:10
Hi WTT, yes I attended the event (albeit online). I felt it was slightly odd in as much as the company presented excellent results in a fairly flat monotone. I guess the CEO was all alone in a room sitting at a desk with a lap top in front of him basically reading the slides. He did elaborate a little on the text but the slides were fairly self explanatory. I have looked this morning and they are not available on their web site, but if they do make them available I will provide a link. That all said the data in the slides clearly showed that the company has turned the corner and produced a stunning performance in 2020. I'm sorry I don't have the exact figures they presented but they have drastically increased sales revenue this year to 9m already and expect to be in excess of 10m by year end, which I believe is more than double last year's sales. They have cut costs by about 15 percent both in terms of administration and R and D. They said again they expect to be in profit this year and significantly cash positive. Some interesting comments they made were that they have a new Chief Operating Officer who is proving very successful at winning new business and they now are winning over 35 percent of contracts they bid for. They said the potential market is substantial and that they are in discussions for lots of new business and expect to win a significant proportion of it. One other interesting comment in response to a question was that although they are pleased with their organic growth they are always considering opportunities for acquisitions and although non have been a good fit yet they would pursue them if they were good enough. My overall conclusion was that the firm have delivered excellent performance in 2020 and are well placed to grow next year and beyond. I hope this helps. As always only my own opinion etc. etc.
stevee1234
15/10/2020
06:47
Did anyone attend the investor presentation last night ? Any views or reports would be welcome.
w t tutte
10/10/2020
10:00
Are COG in any way cahooting with TERN/WYLD also in Cambridge?
oliversanvil
08/10/2020
11:48
I guess that FinnCap valuation is for the company as it stands today but can't associate much value to future potential FDA approvals or major potential new business until it does or doesn't materialise.
stevee1234
08/10/2020
11:25
Yesterday, finnCap reiterated their 80p tp for COG. f
fillipe
08/10/2020
10:25
You make a compelling argument 40 Fathoms and some buyers appear to be agreeing this morning, I think this has some way to go.
stevee1234
07/10/2020
13:22
What is interesting is they get to keep their IP for much of the bespoke and market leading work that they do on behalf of Pharma. This can then be offered to other clients. Nice work if you can get it. This business is grossly undervalued. That is before you even consider a possible positive FDA decision on Aducanumab (pdufa date 7 March 2021), if we get a positive outcome you will see a truly huge step change in the commercial potential for the business. There are only 3 or 4 companies that can offer regulatory approved, highly sensitive, digital administered cognitive test capable of triaging potential Alzheimers patients. Pick your price per test multiply by the tens of millions of tests that will be administered every year, assign COG with a share of those tests. In the context of an already profitable business with a 15 million market cap even crumbs from this will be business changing.
40 fathoms
07/10/2020
07:48
RNS out announcing new contract, I think I judged that one right, looking forward to the 14th.
stevee1234
05/10/2020
12:32
Is there a chance that the presentations on the 14th might encourage us with an upbeat outlook possibly preceded by an RNS giving latest orders.
stevee1234
02/10/2020
18:14
40 Fathoms - many thanks for that, much appreciated!!
dgwinterbottom
02/10/2020
14:20
Two things happened. Firstly, the stock got tipped by Simon Thompson of the IC, his followers poured in and pushed the stock price up massively. Secondly, just as this was happening there were a number of high profile failures in the AD drug development space, this led to some large ongoing trials being cancelled and a number of trials that were being planned to be significantly delayed or cancelled. This did not just hit COG you see it also in the numbers of their competitors. However, because of this COG missed forecast numbers, cash flow neutrality was delayed, Simon Thompson reversed his buy call and then in Feb 2020 additional cash was required to be raised. With the appointment of Matthew Stork last year the company has significantly shifted it focus from R&D to a more commercial outlook the benefits of which we are starting to see now.
40 fathoms
02/10/2020
09:42
Could anyone please explain the reason for the share price drop between Jun 18 & Mar 20. Given the significance of their work I find that quite puzzling
dgwinterbottom
25/9/2020
09:18
Listen to our exclusive interview with Matthew Stork discussing their interim results: hTtps://www.directorstalk.net/cambridge-cognition-really-exciting-position-and-pipeline-of-opportunities-interview/
astonedt
02/9/2020
09:15
Good to see them winning new business, if this continues then FinCap's 75p target should be easily achieved and hopefully significantly surpassed.
stevee1234
30/6/2020
08:47
It's good to see today's finnCap reiteration of their 75p tp for COG. f
fillipe
29/6/2020
14:16
Sir MS - may now be better known as the relatively more recent founder of S4Capital (SFOR) and no longer with WPP? f
fillipe
07/6/2020
13:52
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-160620
dave4545
01/6/2020
18:10
24k of buys all hidden on Nex Exchange today around 29.7p, when that line of stock clears Cog should be back in the 30-35p range again especially if they announce more contracts
dave4545
28/5/2020
10:25
Latest DT interview: Positive pipeline provides ‘big wins for the business’ - https://bit.ly/2X7HtGM
astonedt
27/5/2020
08:27
Many new orders driven by Covid-19,two alone totalling over a million pounds. Very good for an 8 million pound market cap company. Also the CEO suggesting that the need to use this innovative data collection from home could be the catalyst to a fundamentally new way of working with COG well placed to benefit. Good news now but also for the future.
stevee1234
05/5/2020
12:40
It's the block trades that have caused the rise today. Cannacord have been a ten ton weight on this stock for ages now and somebody today has took great chunks of their holding. Once they are completely out this will trade back in the 30-40 range
dave4545
05/5/2020
09:45
Bought back in today after selling out at >£1. Mkt cap of 1 x sales for a co with net cash through to breakeven is way too low Vs market norm.
t0pgrader
21/4/2020
11:20
Interesting that online I cannot get a quote with both brokers for even 5000 shares at 21p
dave4545
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
ADVFN Advertorial
Your Recent History
LSE
COG
Cambridge ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 07:39:57